News
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...
Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...
CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
Shares of CVS Health jumped after the company reported a strong first quarter and agreed to open up access to Novo Nordisk's weight-loss medication at more affordable prices. The stock was up 8.7% at ...
Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.
CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1 ...
CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.
CVS Health reported $1.8 billion in net income for the first quarter, a 58.5% leap, as revenue increased 7% to $94.6 billion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback